# Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised DUTCH PEERS (TWENTE II) trial



Liefke C. van der Heijden<sup>1</sup>, MD; Marlies M. Kok<sup>1</sup>, MD; Marije M. Löwik<sup>1</sup>, PhD; Peter W. Danse<sup>2</sup>, MD, PhD; Gillian A.J. Jessurun<sup>3</sup>, MD, PhD; Raymond W.M. Hautvast<sup>4</sup>, MD, PhD; K. Gert van Houwelingen<sup>1</sup>, MD; Martin G. Stoel<sup>1</sup>, MD, PhD; Marc Hartmann<sup>1</sup>, MD, PhD; Gerard C. Linssen<sup>5</sup>, MD, PhD; Carine J.M. Doggen<sup>6</sup>, PhD; Clemens von Birgelen<sup>1,6\*</sup>, MD, PhD

1. Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands; 2. Department of Cardiology, Rijnstate Hospital, Arnhem, the Netherlands; 3. Department of Cardiology, Treant Zorggroep, Location Scheper, Emmen, the Netherlands; 4. Department of Cardiology, Medical Center Alkmaar, Alkmaar, the Netherlands; 5. Department of Cardiology, Ziekenhuisgroep Twente, Almelo and Hengelo, the Netherlands; 6. Department of Health Technology and Services Research, MIRA - Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, the Netherlands

## **KEYWORDS**

- newer-generation drug-eluting stent
- percutaneous coronary intervention
- Resolute Integrity zotarolimus-eluting stent
- PROMUS Element everolimus-eluting stent

#### Abstract

**Aims:** The aim of this report was to assess the three-year safety and efficacy of implanting newer-generation Resolute Integrity zotarolimus-eluting stents (ZES) versus PROMUS Element everolimus-eluting stents (EES) in all-comers.

**Methods and results:** In the randomised, multicentre, investigator-initiated DUTCH PEERS trial, a total of 1,811 all-comers were 1:1 randomly assigned to treatment with ZES versus EES. A total of 1,293 patients (72%) were treated for complex lesions and 455 patients (25%) were treated for multiple lesions. The primary endpoint target vessel failure (TVF) is a composite of cardiac death, target vessel-related myocardial infarction or target vessel revascularisation. Adverse clinical events were independently adjudicated. Three-year follow-up data were obtained in 1,807 patients (99.8%, four withdrawals). Both the ZES and EES groups showed favourable outcomes with a similar incidence of TVF (10.7% vs. 10.3%;  $p_{Log-rank}=0.77$ ) and the individual components thereof: cardiac death (3.2% vs. 3.1%;  $p_{Log-rank}=0.87$ ), target vessel-related myocardial infarction (2.8% vs. 2.2%;  $p_{Log-rank}=0.44$ ) and target vessel revascularisation (6.0% vs. 6.2%;  $p_{Log-rank}=0.87$ ). In addition, the incidence of definite or probable stent thrombosis was similar for patients treated with ZES versus EES (1.4% vs. 1.1%;  $p_{Log-rank}=0.66$ ).

**Conclusions:** The safety and efficacy of treating all-comers with newer-generation Resolute Integrity and PROMUS Element stents was found to be extended up to three years.

\**Corresponding author: Thoraxcentrum Twente, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, the Netherlands. E-mail: c.vonbirgelen@mst.nl* 

DOI: 10.4244/EIJ-D-16-00571

## **Abbreviations**

DES	drug-eluting stent
EES	everolimus-eluting stent
MI	myocardial infarction
TVF	target vessel failure
ZES	zotarolimus-eluting stent

#### Introduction

Newer-generation metallic drug-eluting stents (DES), such as the cobalt-chromium-based Resolute Integrity<sup>®</sup> zotarolimus-eluting stent (ZES) (Medtronic, Minneapolis, MN, USA) and the platinum-chromium-based PROMUS Element<sup>™</sup> everolimus-eluting stent (EES) (Boston Scientific, Marlborough, MA, USA), have stent designs that were developed to facilitate deliverability and further improve DES apposition<sup>1,2</sup>. Both DES were compared for the first time in the randomised DUTCH PEERS trial, which was also the first trial ever to investigate Resolute Integrity. In 1,811 all-comers, this study demonstrated non-inferiority of the ZES versus the EES at 12-month follow-up<sup>1</sup>. Long-term data from the DUTCH PEERS trial are of interest, as certain between-stent differences may only be discovered after years. We therefore assessed the three-year clinical outcome of percutaneous coronary interventions in the two DES arms.


#### **Methods**

The design of the study, definitions of clinical endpoints and characteristics of patients, lesions and procedures of the multicentre, patient-blinded, investigator-initiated, 1:1 randomised DUTCH PEERS (TWENTE II) trial (ClinicalTrials.gov NCT01331707) have been reported previously<sup>1</sup>. DUTCH PEERS enrolled 1,811 patients with any type of clinical syndrome, including 20.4% of patients with ST-elevation myocardial infarction (MI), 24.7% with non-ST-elevation MI and 71.7% with complex coronary lesions<sup>1</sup>. The external CRO Diagram (Zwolle, the Netherlands) monitored clinical outcome in 10% of randomly selected patients and organised the adjudication of adverse events by an independent clinical events committee for both two- and three-year follow-up. The DUTCH PEERS trial complied with the Declaration of Helsinki and was approved by the Medical Ethics Committee Twente and the institutional review boards of all participating centres. All patients provided written informed consent. Clinical endpoints were defined according to the Academic Research Consortium (ARC), including the addendum on MI<sup>3,4</sup>. The primary endpoint was target vessel failure (TVF) at one year, a composite of cardiac death, target vessel-related MI and clinically indicated target vessel revascularisation. P-values and confidence intervals were two-sided and p-values <0.05 were considered significant. Statistics were performed as previously reported<sup>4</sup>, using SPSS, Version 22.0 (IBM Corp., Armonk, NY, USA).

#### Results

Three-year follow-up was obtained from 1,807 patients (99.8%; four consent withdrawals). Patients treated with Resolute Integrity ZES (n=906) and PROMUS Element EES (n=905) showed favourable outcomes with similar TVF rates (10.7% vs. 10.3%;  $p_{Log-rank}=0.77$ ) (Table 1, Figure 1). The incidence of the individual components of TVF was similar for both DES: cardiac death (3.2% vs. 3.1%;  $p_{Log-rank}=0.87$ ); target vessel-related MI (2.8% vs. 2.2%;  $p_{Log-rank}=0.44$ ); and target vessel revascularisation (6.0% vs. 6.2%;  $p_{Log-rank}=0.87$ ) (Table 1, Figure 1). At three-year follow-up, 6.1% of patients treated with Resolute Integrity ZES and 7.1% of patients treated with PROMUS Element ZES were on dual antiplatelet therapy.


	Outcome at 3 years				Outcome difference between 1 and 3 years					
	Resolute Integrity ZES	PROMUS Element EES	Hazard ratio (95% CI)	<b>p</b> <sub>Log-rank</sub>	Resolute Integrity ZES	PROMUS Element EES	Difference (95% CI)	<i>p</i> -value		
Death (any)	48 (5.3)	43 (4.8)	1.13 (0.75-1.70)	0.57	26 (2.9)	31 (3.5)	-0.5 (-2.2-1.1)	0.53		
Cardiac death	29 (3.2)	28 (3.1)	1.04 (0.62-1.76)	0.87	14 (1.6)	18 (2.0)	-0.4 (-1.7-0.8)	0.50		
Target vessel myocardial infarction	25 (2.8)	20 (2.2)	1.26 (0.70-2.26)	0.44	5 (0.6)	8 (0.9)	-0.3 (-1.1-0.5)	0.42		
Clinically indicated target vessel revascularisation	53 (6.0)	55 (6.2)	0.97 (0.67-1.41)	0.87	29 (3.4)	29 (3.3)	0.0 (-1.7-1.7)	0.98		
Clinically indicated target lesion revascularisation	42 (4.7)	39 (4.4)	1.09 (0.70-1.68)	0.71	22 (2.5)	19 (2.2)	0.4 (-1.1-1.8)	0.61		
Target vessel failure	96 (10.7)	93 (10.3)	1.04 (0.79-1.39)	0.77	41 (4.9)	46 (5.4)	-0.5 (-2.6-1.6)	0.63		
Target lesion failure	88 (9.7)	81 (8.9)	1.10 (0.82-1.49)	0.53	37 (4.4)	40 (4.6)	-0.3 (-2.2-1.7)	0.79		
Major adverse cardiac events	106 (11.7)	103 (11.4)	1.04 (0.79-1.37)	0.77	48 (5.7)	59 (6.9)	-1.2 (-3.5-1.1)	0.31		
Patient-oriented composite endpoint	148 (16.4)	154 (17.0)	0.97 (0.77-1.21)	0.76	66 (8.0)	80 (9.6)	-1.6 (-4.3-1.1)	0.25		
Definite or probable stent thrombosis	12 (1.4)	10 (1.1)	1.21 (0.52-2.79)	0.66	7 (0.8)	2 (0.2)	0.6 (-0.1-1.2)	0.11		
Definite stent thrombosis	9 (1.0)	8 (0.9)	1.13 (0.44-2.93)	0.80	6 (0.7)	2 (0.2)	0.5 (-0.2-1.1)	0.18		
Values are n (%). *Definitions of clinical endpoints have been reported previously. CI: confidence interval										



**Figure 1.** Kaplan-Meier curves for target vessel failure and individual components. A) Target vessel failure. B) Cardiac death. C) Target vessel-related myocardial infarction. D) Target vessel revascularisation. Patients treated with Resolute Integrity (red) versus PROMUS Element stents (grey).

As shown in **Table 1** and **Figure 2**, the rates of definite and definite or probable stent thrombosis were low for patients treated with Resolute Integrity ZES and PROMUS Element EES (1.0% vs. 0.9%;  $p_{Log-rank}=0.80$  and 1.4% vs. 1.1%;  $p_{Log-rank}=0.66$ , respectively). Due to an apparent dissimilarity between the Resolute Integrity ZES and PROMUS Element EES groups in the course of their time-to-event

curves for definite or probable stent thrombosis (catch-up after >1 year vs. main increase within first 12 months) (Figure 2), we performed *post hoc* a landmark analysis at 12-month follow-up. Definite or probable stent thrombosis occurred during the first year in 0.6% vs. 0.9% ( $p_{Log-rank}=0.41$ ) of patients and during the second plus third years in 0.8% vs. 0.2% ( $p_{Log-rank}=0.09$ ) of patients.



**Figure 2.** Kaplan-Meier curve for stent thrombosis. Patients treated with Resolute Integrity (red) versus PROMUS Element stents (grey). Dual antiplatelet therapy (DAPT) means acetylsalicylic acid plus P2Y, receptor antagonist.

## Three-year outcome of DUTCH PEERS trial

# Discussion

The current study reports the three-year clinical outcome of the DUTCH PEERS trial, which is the first randomised study to compare Resolute Integrity ZES versus PROMUS Element EES in all-comers<sup>1</sup>. Patients of both stent arms had similar and relatively low rates of the main clinical endpoint TVF (10.7% vs. 10.3%), and the incidence of definite or probable stent thrombosis was low and comparable (1.4% vs. 1.1%).

Our findings corroborate the results of previous randomised studies, that compared the predecessors of these newer-generation DES in broad patient populations<sup>5,6</sup>. Long-term outcome data about Resolute Integrity ZES and PROMUS Element EES in all-comers are scarce. The only randomised trial other than DUTCH PEERS that studied Resolute Integrity in all-comers is the SORT OUT VI study<sup>2</sup>, but definite long-term results of that study have not yet been published. In addition, the PLATINUM trial is the only randomised trial that has published three-year follow-up data on the use of PROMUS Element in low-to-moderate risk patients (e.g.,  $\leq 2 \ de \ novo$  lesions in vessels  $\geq 2.5 \ mm$ ), showing similar safety and efficacy for both PROMUS Element and XIENCE V<sup>®</sup> (Abbott Vascular, Santa Clara, CA, USA)<sup>7</sup>. Our current three-year follow-up data support these favourable findings in a broader, greatly unrestricted patient population.

As the present study was not powered to assess between-group differences in secondary clinical endpoints, these findings should be considered hypothesis-generating.

## Conclusions

The safety and efficacy of treating all-comers with newer-generation Resolute Integrity and PROMUS Element stents in the randomised DUTCH PEERS trial was extended up to three years.

## Impact on daily practice

The three-year results of the DUTCH PEERS trial are the first long-term data in all-comers from a randomised comparison of the newer-generation Resolute Integrity ZES and the PROMUS Element EES, two stents that are often used in routine clinical practice. The consistently low rates of adverse clinical events, such as target vessel myocardial infarction, target vessel revascularisation and definite or probable stent thrombosis, provide a strong signal of sustained safety and efficacy of both metallic drug-eluting stents in this broad patient population. These long-term outcome data fill a gap in the literature and might in the future be useful for interpreting long-term data following broader applications of bioresorbable scaffolds.

## Funding

This investigator-initiated study was supported equally by Boston Scientific and Medtronic.

## Conflict of interest statement

C. von Birgelen was a consultant to Boston Scientific and Medtronic, and has received lecture fees from AstraZeneca and Biotronik. The institution has received research grants provided by AstraZeneca, Biotronik, Boston Scientific, and Medtronic. The other authors have no conflicts of interest to declare.

#### References

1. von Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GA, Hautvast RW, van Houwelingen KG, Schram AR, Tjon Joe Gin RM, Louwerenburg JW, de Man FH, Stoel MG, Löwik MM, Linssen GC, Saïd SA, Nienhuis MB, Verhorst PM, Basalus MW, Doggen CJ, Tandjung K. Third-generation zotarolimus-eluting and everolimuseluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. *Lancet.* 2014;383:413-23.

2. Raungaard B, Okkels Jensen LO, Tilsted HH, Christiansen EH, Maeng M, Terkelsen CJ, Krusell LR, Kaltoft A, Kristensen SD, Bøtker HE, Thuesen L, Aarøe J, Jensen SE, Villadsen AB, Thayssen P, Veien KT, Hansen KN, Junker A, Madsen M, Ravkilde J, Lassen JF; Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT). Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. *Lancet.* 2015;385:1527-35.

3. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation*. 2007;115:2344-51.

4. Vranckx P, Cutlip DE, Mehran R, Kint PP, Silber S, Windecker S, Serruys PW. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. *EuroIntervention*. 2010;5:871-4.

5. Iqbal J, Serruys PW, Silber S, Kelbaek H, Richardt G, Morel MA, Negoita M, Buszman PE, Windecker S. Comparison of zotarolimusand everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comerstrial. *Circ Cardiovasc Interv.* 2015;8:e002230.

6. Lowik MM, Lam MK, Sen H, Tandjung K, van Houwelingen KG, de Man FH, Stoel MG, Louwerenburg JH, Linssen GC, Doggen CJ, von Birgelen C. Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial. *EuroIntervention*. 2015;10:1276-9.

7. Meredith IT, Teirstein PS, Bouchard A, Carrié D, Möllmann H, Oldroyd KG, Hall J, Allocco DJ, Dawkins KD, Stone GW. Threeyear results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM trial). *Am J Cardiol.* 2014;113:1117-23.